Company research
VIVOS INC
CIK 1449349Updated Nov 13, 2026
SecurityRDGL · OTC · equity
Name history
ADVANCED MEDICAL ISOTOPE Corp · through Dec 18, 2017
RDGL price & chart
Loading TradingView…
OTC:RDGL on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
DEF 14A filing
Unregistered Sales of Equity Securities · Shareholder Director Nominations · Other Events
Items 3.02, 5.08, 8.01, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 1.01, 3.02, 3.03, 5.03, 9.01
8-K filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 2,295,185Source | 1,244,325Source | 2,879,570Source | 2,775,556Source | 1,769,665Source | 2,950,505Source | 3,301,867Source | 1,382,329Source | 1,867,583Source | 2,233,456Source | 1,610,124Source | 1,742,736Source |
| Property, Plant and Equipment, NetUSD | — | — | 338,236Source | — | — | 244,055Source | — | — | 102,811Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 1,218,160Source | — | — | 1,724,417Source | — | 3,265,100Source | 1,370,829Source | — | 2,212,548Source | 1,592,287Source | 1,706,065Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 4,699Source | 5,000Source | 15,650Source | 13,270Source | 13,500Source | 7,668Source | 8,704Source | 11,500Source | 22,331Source | 10,326Source | 7,000Source | 11,000Source |
| Inventory, NetUSD | 62,734Source | — | 56,427Source | 62,961Source | — | 56,863Source | 21,198Source | — | 57,257Source | — | — | — |
| Assets, CurrentUSD | 2,295,185Source | 1,244,325Source | 2,440,973Source | 2,775,556Source | 1,769,665Source | 2,599,386Source | 3,301,867Source | 1,382,329Source | 1,651,069Source | 2,233,456Source | 1,610,124Source | 1,742,736Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 97,361Source | — | — | 104,064Source | — | — | 110,703Source | — | — | — |
| Other Assets, NoncurrentUSD | — | — | 3,000Source | — | — | 3,000Source | — | — | 3,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 112,693Source | 48,820Source | 123,955Source | 96,458Source | 166,560Source | 253,195Source | 115,378Source | 74,766Source | 206,743Source | 86,209Source | 245,004Source | 81,692Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 454,665Source | 417,593Source | 494,214Source | 453,804Source | 417,681Source | 482,841Source | 453,412Source | 390,034Source | 455,494Source | 440,874Source | 387,894Source | 362,541Source |
| Retained Earnings (Accumulated Deficit)USD | -87,348,732Source | -84,338,041Source | -90,442,280Source | -86,841,438Source | -83,512,778Source | -89,612,091Source | -86,195,925Source | -83,009,320Source | -88,427,246Source | -85,361,229Source | -82,450,781Source | -79,556,028Source |
| Stockholders' Equity Attributable to ParentUSD | 2,182,492Source | 1,195,505Source | 2,755,615Source | 2,679,098Source | 1,603,105Source | 2,697,310Source | 3,183,489Source | 1,307,563Source | 1,660,840Source | 2,147,247Source | 1,365,120Source | 1,661,044Source |
| Additional Paid in Capital, Common StockUSD | 79,726,600Source | 75,479,376Source | 83,353,722Source | 79,716,773Source | 75,061,625Source | 82,476,601Source | 79,579,043Source | 74,290,272Source | 80,282,633Source | 77,719,143Source | 73,791,430Source | 71,217,954Source |
| Liabilities and EquityUSD | 2,295,185Source | 1,244,325Source | 2,879,570Source | 2,775,556Source | 1,769,665Source | 2,950,505Source | 3,301,867Source | 1,382,329Source | 1,867,583Source | 2,233,456Source | 1,610,124Source | 1,742,736Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 112,693Source | 48,820Source | 49,973Source | 96,458Source | 166,560Source | 171,737Source | 115,378Source | 74,766Source | 117,892Source | 86,209Source | 245,004Source | 81,692Source |
| Operating Lease, Liability, CurrentUSD | — | — | 29,171Source | — | — | 28,135Source | — | — | 25,420Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | — | — | 73,982Source | — | — | 81,458Source | — | — | 88,851Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -14,663Source | -1,622Source | 12,005Source | 3,326Source | -4,000Source | 11,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -394Source | 21,198Source | 57,257Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -429,861Source | -455,198Source | -2,057,743Source | -1,684,039Source | -1,293,023Source | -1,120,058Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -151,205Source | — | -103,185Source | — | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 151,205Source | — | 103,185Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,548,323Source | 1,507,750Source | 1,506,905Source | 2,304,300Source | 1,179,245Source | 1,220,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 967,257Source | 1,052,552Source | -654,023Source | 620,261Source | -113,778Source | 99,942Source |
| Additional Financial Items | ||||||||||||
| DepreciationUSD | — | — | — | — | — | — | 9,961Source | — | 374Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 47,588Source |
| General and Administrative ExpenseUSD | — | — | 72,904Source | 65,123Source | 82,278Source | 80,913Source | 58,685Source | 52,203Source | 296,556Source | 241,824Source | 165,773Source | 151,111Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -507,294Source | -825,263Source | -830,189Source | -645,513Source | -1,184,845Source | -834,696Source | -3,066,017Source | -2,910,448Source | -2,894,753Source | -2,470,161Source |
| Nonoperating Income (Expense)USD | — | — | 23,729Source | 17,882Source | -175,660Source | 29,260Source | -639,353Source | 28,836Source | 99,030Source | -306,064Source | -101,607Source | 47,588Source |
| Operating ExpensesUSD | — | — | 518,208Source | 844,226Source | 652,809Source | 640,020Source | 537,474Source | 854,449Source | 3,105,292Source | 2,601,400Source | 2,787,110Source | 2,525,469Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 6,638Source | — | 4,413Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 2,266,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,879Source | 5,000Source | 36,400Source | 15,000Source | 36,068Source | 26,748Source | 68,379Source | 27,995Source | 19,500Source | 36,499Source |
| Cost of RevenueUSD | — | — | 14,694Source | 3,919Source | 38,120Source | 49,753Source | 44,086Source | 35,831Source | 128,134Source | 30,979Source | 25,536Source | 28,779Source |
| Operating Income (Loss)USD | — | — | -531,023Source | -843,145Source | -654,529Source | -674,773Source | -545,492Source | -863,532Source | -3,165,047Source | -2,604,384Source | -2,793,146Source | -2,517,749Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -507,294Source | -825,263Source | -830,189Source | -645,513Source | -1,184,845Source | -834,696Source | -3,066,017Source | -2,910,448Source | -2,894,753Source | -2,470,161Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -507,294Source | -825,263Source | -830,189Source | -645,513Source | -1,184,845Source | -834,696Source | -3,066,017Source | -2,910,448Source | -2,894,753Source | -2,470,161Source |
| Earnings Per Share, BasicUSD per share | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | -0.01Source | -0.01Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | -0.01Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 454,304,627Source | 418,629,728Source | 490,699,399Source | 453,511,129Source | 462,160,317Source | 448,234,917Source | 452,722,074Source | 409,673,533Source | 368,805,214Source | 351,425,912Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 454,304,627Source | 418,629,728Source | 490,699,399Source | 453,511,129Source | 462,160,317Source | 448,234,917Source | 452,722,074Source | 409,673,533Source | 368,805,214Source | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 72,904Source | 65,123Source | 82,278Source | 80,913Source | 58,685Source | 52,203Source | 296,556Source | 241,824Source | 165,773Source | 151,111Source |
| Gross ProfitUSD | — | — | -12,815Source | 1,081Source | -1,720Source | -34,753Source | -8,018Source | -9,083Source | -59,755Source | -2,984Source | -6,036Source | 7,720Source |
| Interest Income (Expense), NetUSD | — | — | 23,729Source | 17,882Source | 20,340Source | 29,260Source | 12,275Source | 28,836Source | 99,030Source | 74,936Source | 49,577Source | — |
| Labor and Related ExpenseUSD | — | — | 89,447Source | 85,400Source | 159,884Source | 92,687Source | 155,434Source | 94,697Source | 417,097Source | 352,597Source | 281,716Source | 275,240Source |
| Nonoperating Income (Expense)USD | — | — | 23,729Source | 17,882Source | -175,660Source | 29,260Source | -639,353Source | 28,836Source | 99,030Source | -306,064Source | -101,607Source | 47,588Source |
| Operating ExpensesUSD | — | — | 518,208Source | 844,226Source | 652,809Source | 640,020Source | 537,474Source | 854,449Source | 3,105,292Source | 2,601,400Source | 2,787,110Source | 2,525,469Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 6,638Source | — | 4,413Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 67,820Source | 66,551Source | 49,182Source | 107,965Source | 37,923Source | 119,281Source | 352,232Source | 324,629Source | 732,698Source | 343,802Source |
Filing attachments
ex4-1.htm · 1-A/A · 2026-03-04
Exhibit 4.1 VIVOS INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES. THE SECURITIES OFFERED HEREB…
Read attachment ↗ex99-1.htm · 8-K · 2025-02-10
EX-99.1 2 ex99-1.htm Exhibit 99.1 Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans ( Richland, WA - February 4, 2025 ) - Vivos Inc. (OTCQB: RDGL) is pleased to report that the first five patients demonstrated the safety of RadioGel Precision Radionuclide Therapy TM by satisfying the criteria in the Clinical Study Plan, including confirmation via PET imaging that the Y-90 remained at the point of injection and no adverse events reported by any of the …
Read attachment ↗